Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $13.76 Average PT from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been assigned a consensus rating of "Reduce" from the twenty analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, seventeen have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.76.

SAGE has been the subject of a number of research analyst reports. TD Cowen downgraded Sage Therapeutics from a "buy" rating to a "hold" rating and cut their target price for the stock from $16.00 to $10.00 in a research report on Tuesday, July 30th. The Goldman Sachs Group reduced their price objective on Sage Therapeutics from $19.00 to $11.00 and set a "neutral" rating for the company in a research note on Friday, July 26th. HC Wainwright reissued a "neutral" rating and set a $25.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, October 9th. Mizuho reduced their price objective on Sage Therapeutics from $18.00 to $16.00 and set a "neutral" rating for the company in a research note on Friday, July 19th. Finally, JPMorgan Chase & Co. reduced their price objective on Sage Therapeutics from $12.00 to $10.00 and set a "neutral" rating for the company in a research note on Tuesday, August 6th.

Institutional Trading of Sage Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SAGE. Bellevue Group AG raised its holdings in Sage Therapeutics by 27.1% during the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company's stock valued at $83,684,000 after buying an additional 952,193 shares in the last quarter. Federated Hermes Inc. bought a new position in Sage Therapeutics during the second quarter valued at about $7,281,000. Renaissance Technologies LLC raised its holdings in Sage Therapeutics by 1,476.6% during the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company's stock valued at $6,010,000 after buying an additional 518,296 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Sage Therapeutics by 831.2% during the second quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company's stock valued at $5,312,000 after buying an additional 436,566 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company's stock valued at $107,781,000 after buying an additional 432,013 shares in the last quarter. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Down 0.7 %

Shares of NASDAQ:SAGE traded down $0.06 during trading on Tuesday, hitting $8.48. 860,794 shares of the company traded hands, compared to its average volume of 971,399. Sage Therapeutics has a one year low of $5.84 and a one year high of $28.26. The stock has a market capitalization of $510.34 million, a price-to-earnings ratio of -1.01 and a beta of 0.91. The business's fifty day moving average is $7.52 and its 200-day moving average is $10.05.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by ($0.02). The business had revenue of $8.65 million during the quarter, compared to the consensus estimate of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business's quarterly revenue was up 249.8% compared to the same quarter last year. During the same period last year, the company earned ($2.68) earnings per share. On average, analysts forecast that Sage Therapeutics will post -6.43 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.